Parameters considered for the univariate and multivariable models
| Patient data: |
| Age* |
| Karnofsky score† |
| CMV serology† |
| Disease data: |
| WBC count at diagnosis (× 109/L)* |
| Cytogenetics† |
| BM blasts at BMT (%)* |
| Disease stage at BMT† |
| Time from diagnosis to BMT* |
| Donor data: |
| Age* |
| CMV serology† |
| Transplant data: |
| Year of transplant* |
| HLA matching† |
| TBI applied† |
| Ara-C or VP-16 added to TBI† |
| Marrow cell dose* |
| T-cell depletion† |
| MTX + CSA included for GVH prophylaxis† |
| ALG included in conditioning† |
| Patient data: |
| Age* |
| Karnofsky score† |
| CMV serology† |
| Disease data: |
| WBC count at diagnosis (× 109/L)* |
| Cytogenetics† |
| BM blasts at BMT (%)* |
| Disease stage at BMT† |
| Time from diagnosis to BMT* |
| Donor data: |
| Age* |
| CMV serology† |
| Transplant data: |
| Year of transplant* |
| HLA matching† |
| TBI applied† |
| Ara-C or VP-16 added to TBI† |
| Marrow cell dose* |
| T-cell depletion† |
| MTX + CSA included for GVH prophylaxis† |
| ALG included in conditioning† |
CMV indicates cytomegalovirus; TBI, total body irradiation; Ara-C, cytarabin; VP-16, etoposide; MTX + CSA, methotrexate + cyclosporin A; GVH, graft-versus-host; ALG, antilymphocyte globulin.
Continuous variables were treated as categorical in the univariate analysis, typically with the variables split at their medians.
Continuous variable.
Categorical variable.